[go: up one dir, main page]

MX2018005165A - Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2. - Google Patents

Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2018005165A
MX2018005165A MX2018005165A MX2018005165A MX2018005165A MX 2018005165 A MX2018005165 A MX 2018005165A MX 2018005165 A MX2018005165 A MX 2018005165A MX 2018005165 A MX2018005165 A MX 2018005165A MX 2018005165 A MX2018005165 A MX 2018005165A
Authority
MX
Mexico
Prior art keywords
masp
complement activation
dependent complement
methods
treatment
Prior art date
Application number
MX2018005165A
Other languages
English (en)
Inventor
Thomas Dudler
Demopulos Gregory A
Hans - Wilhelm SCHWAEBLE
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2018005165A publication Critical patent/MX2018005165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Power Steering Mechanism (AREA)
  • Exhaust Gas After Treatment (AREA)

Abstract

En un aspecto, la invencion proporciona metodos para la inhibicion de los efectos de la activacion del complemento dependiente de MASP-2 en un sujeto humano que padece TMA asociada con trasplante de celulas madre hematopoyeticas. Los metodos comprenden la etapa de administrar, a un sujeto que lo necesite, una cantidad de un agente inhibidor de MASP-2 efectiva para inhibir la activacion del complemento dependiente de MASP-2.
MX2018005165A 2015-11-09 2016-11-09 Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2. MX2018005165A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252814P 2015-11-09 2015-11-09
US201662406726P 2016-10-11 2016-10-11
PCT/US2016/061113 WO2017083371A1 (en) 2015-11-09 2016-11-09 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (1)

Publication Number Publication Date
MX2018005165A true MX2018005165A (es) 2020-11-11

Family

ID=58691444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005165A MX2018005165A (es) 2015-11-09 2016-11-09 Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
MX2023001193A MX2023001193A (es) 2015-11-09 2018-04-25 Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001193A MX2023001193A (es) 2015-11-09 2018-04-25 Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.

Country Status (19)

Country Link
US (3) US20170137537A1 (es)
EP (1) EP3373963A4 (es)
JP (2) JP6814802B2 (es)
KR (2) KR102432062B1 (es)
CN (2) CN117398458A (es)
AU (2) AU2016354117B2 (es)
CA (1) CA3004753C (es)
CL (1) CL2018001258A1 (es)
EA (1) EA201891132A1 (es)
GE (3) GEP20247583B (es)
IL (2) IL259225B (es)
MD (1) MD4685C1 (es)
MX (2) MX2018005165A (es)
MY (1) MY197758A (es)
NZ (1) NZ742987A (es)
PH (1) PH12018501009A1 (es)
SG (2) SG10202011469UA (es)
UA (1) UA124094C2 (es)
WO (1) WO2017083371A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139081A2 (en) 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
KR102677379B1 (ko) 2013-10-17 2024-06-24 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
US20200078215A1 (en) * 2016-07-06 2020-03-12 MicroOptx Inc. Glaucoma treatment devices and methods
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TW202529812A (zh) 2017-08-15 2025-08-01 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
CN111278863A (zh) * 2017-08-25 2020-06-12 奥默罗斯公司 高浓缩低粘度masp-2抑制性抗体制剂、试剂盒和治疗患有非典型溶血综合征的受试者的方法
CN119350433A (zh) 2018-05-29 2025-01-24 奥默罗斯公司 Masp-2抑制剂和使用方法
WO2019246367A1 (en) * 2018-06-22 2019-12-26 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
IL293363A (en) * 2019-11-26 2022-07-01 Omeros Corp Masp-2 inhibitors for use in treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
WO2023108028A2 (en) 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
WO2025153000A1 (zh) * 2024-01-17 2025-07-24 信立泰(成都)生物技术有限公司 一种抗masp2抗体或其抗原结合片段及用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340831C (en) 1987-12-15 1999-11-30 Wayne Lyle Gerlach Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
CA2378880C (en) 1999-07-21 2010-02-23 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
WO2001012212A1 (en) * 1999-08-13 2001-02-22 The Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
KR101101261B1 (ko) 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2012139081A2 (en) 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
CA3131223C (en) 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
JP6445972B2 (ja) * 2012-06-18 2018-12-26 オメロス コーポレーション 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2921856A1 (en) * 2013-09-16 2015-03-19 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
KR102677379B1 (ko) 2013-10-17 2024-06-24 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
KR102011118B1 (ko) * 2018-04-13 2019-08-14 김정범 개선된 스냅 단추

Also Published As

Publication number Publication date
KR102277166B1 (ko) 2021-07-15
IL259225B (en) 2022-09-01
GEAP202314803A (en) 2023-06-26
KR20210090283A (ko) 2021-07-19
CA3004753A1 (en) 2017-05-18
IL295200B2 (en) 2025-04-01
BR112018009311A8 (pt) 2019-02-26
CN108472347A (zh) 2018-08-31
AU2016354117B2 (en) 2019-11-28
EP3373963A1 (en) 2018-09-19
US11981749B2 (en) 2024-05-14
UA124094C2 (uk) 2021-07-21
JP7629300B2 (ja) 2025-02-13
WO2017083371A1 (en) 2017-05-18
KR102432062B1 (ko) 2022-08-12
US20240343830A1 (en) 2024-10-17
MX2023001193A (es) 2023-08-11
SG10202011469UA (en) 2020-12-30
CA3004753C (en) 2023-02-28
NZ742987A (en) 2019-12-20
MD20180042A2 (ro) 2018-09-30
IL259225A (en) 2018-07-31
MD4685C1 (ro) 2020-12-31
GEP20237574B (en) 2023-12-25
SG11201803834UA (en) 2018-06-28
MD4685B1 (ro) 2020-03-31
KR20180074789A (ko) 2018-07-03
AU2016354117A1 (en) 2018-05-10
US20170137537A1 (en) 2017-05-18
JP2021063093A (ja) 2021-04-22
GEP20247583B (en) 2024-01-10
US20210047433A1 (en) 2021-02-18
EA201891132A1 (ru) 2018-10-31
PH12018501009A1 (en) 2019-01-28
BR112018009311A2 (pt) 2018-11-06
EP3373963A4 (en) 2019-07-10
CN117398458A (zh) 2024-01-16
IL295200A (en) 2022-10-01
AU2020201500A1 (en) 2020-03-19
IL295200B1 (en) 2024-12-01
JP6814802B2 (ja) 2021-01-20
CL2018001258A1 (es) 2018-10-12
MY197758A (en) 2023-07-13
JP2018533592A (ja) 2018-11-15
CN108472347B (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2018005165A (es) Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
CL2022000195A1 (es) Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2018000429A1 (es) Moduladores de la expresión de kras
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CY1120950T1 (el) Θεραπεια ινωσης
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
ECSP17038455A (es) Combinaciones de compuestos activos
ECSP17038476A (es) Combinaciones de compuestos activos
ECSP17038441A (es) Combinaciones de compuestos activos
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
CL2017002967A1 (es) Beta-caseinas a2 y capacidad antioxidante.
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.